Firebrick Pharma Limited (ASX:FRE)

Revenue by Product

Financials in millions AUD. Fiscal year is July - June.

Year Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Povidone-iodine (PVP-I)	14.52K
Povidone-iodine (PVP-I) Growth	1649.64%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Year Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022
Australia	14.52K
Australia Growth	1649.64%